Meanwhile, growing subsequent evidence suggest that aberrant overexpression of UCA1 is associated with high risk of poor outcome or clinicopathological characteristics in breast cancer, colorectal cancer, bladder cancer, esophageal squamous cell carcinoma, epithelial ovarian cancer, gastric cancer, hepatocellular carcinoma, melanoma, non-small cell lung cancer, prostate cancer and tongue squamous cell carcinoma [11–13, 15–27]. The gene discussed is UCA1; the disease is non-small cell lung carcinoma.